Back to Authors

Bidadi, Behzad

Mayo Clinic

Merck & Co., Inc., Rahway, NJ, USA (United States)

Citations 3

Treatment of generalized infantile myofibromatosis with sorafenib and imatinib: A case report
Bidadi, Behzad, Watson, Andrea , Weigel, Brenda J. , Oliveira, André M. , Kirkham, Justin K. , Arndt, Carola, Oliveira, Andre, Kirkham, Justin

Pediatric Blood & Cancer | April 20, 2020 | Volume: 67 | Issue: 6 | Pages: No page available

10.1002/pbc.28288 Get It

AbstractInfantile myofibromatosis (IM) is characterized by solitary musculoskeletal nodules presenting during infancy but can manifest as multiple lesions with visceral involvement. Multicentric IM with visceral involvement carries a high risk of mortality and there is no consensus on treatment. We present a case of a patient with multicentric IM and pulmonary involvement who progressed on several chemotherapeutic regimens and subsequently had a complete response to sorafenib and later imatinib. This report describes the novel use of sorafenib and imatinib to treat generalized IM and the role of continued tyrosine kinase inhibitor therapy to maintain remission.
Abstract 5488: Utilizing a pathway based analysis of genome wide association data to identify biomarkers of toxicity in breast cancer patients
Bidadi, Behzad, Rübner, Matthias, Hein, Alexander , Beckmann, Matthias W. , Fasching, Peter A. , Rack, Brigitte , Janni, Wolfgang, Weinshilboum, Richard, Wang, Liewei , Kalari, Krishna R. , Hein, Alexander

Cancer Research | August 5, 2015 | Volume: 75 | Issue: 15_Supplement | Pages: 5488-5488

10.1158/1538-7445.am2015-5488 Get It

Abstract Breast cancer is the most common invasive cancer in women worldwide and treatment related toxicity has high inter-patient variability. Our goal was to identify additional genetic predictors of toxicity by completing a pathway based analysis taking advantage of the genotyping results obtained through a GWAS of the same patients. For our analysis, we have utilized GWA data from the SUCCESS-A trial in which 3,754 breast cancer patients were treated with adjuvant chemotherapy. We have included SNPs associated with 112 genes involved in drug disposition and 375 genes in selected cancer pathways. We identified 35 SNPs associated with neutropenia (P-value <1×10−4). These patients initially received three cycles consisting of 5-fluorouracil (5-FU), cyclophosphamide, and epirubicin. Currently we are characterizing the function of three SNPs located within an intron of the hyaluronan mediated motility receptor (HMMR) gene that are associated with the neutropenia phenotype (P-value <1×10−4). These SNPs are highly associated with the expression of a gene encoding a B-cell survival factor, TNFSF13B, (P-value <1×10−5). Our in vitro studies using lymphoblastoid cell lines (LCLs) selected based on the genotypes of HMMR gene showed that heterozygous and homozygous variant cells (n = 6) have an increased sensitivity to 5-fluorouracil, but not cyclophosphamide or epirubicin when compared with homozygous wild-type cells (n = 6). LCLs exposed to the previously mentioned chemotherapeutic agents resulted in an upregulation of TNFSF13B gene expression and downregulation of HMMR gene expression. We have utilized a pathway based approach to analyzing GWA data to identify several SNPs in the HMMR gene highly associated with the expression of one of the top signals in the cytopenia GWAS. Our goal is to further characterize the role of HMMR gene variants in chemotherapy response by assessing whether combinations of these agents in vitro (including 5-FU) also have a genotype dependent response to cytotoxicity. Citation Format: Behzad Bidadi, Krishna R. Kalari, Matthias Rubner, Alexander Hein, Matthias W. Beckmann, Peter A. Fasching, Brigitte Rack, Wolfgang Janni, Richard Weinshilboum, Liewei Wang. Utilizing a pathway based analysis of genome wide association data to identify biomarkers of toxicity in breast cancer patients. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 5488. doi:10.1158/1538-7445.AM2015-5488
Adolescent With Lymphadenopathy in the Absence of Systemic Symptoms
Bidadi, Behzad, Uzodi, Adaora S. , Pritt, Bobbi S. , Khan, Shakila P. , Henry, Nancy K., Pritt, Bobbi S

Clinical Pediatrics | March 2, 2015 | Volume: 54 | Issue: 12 | Pages: 1221-1223

10.1177/0009922815574082 Get It